NCT04998864View on ClinicalTrials.gov

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients

UnknownOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2023

Conditions
Glioma, MalignantGlioblastoma
Interventions
DEVICE

Magnetic Resonance guided Focused ultrasound (MRgFUS)

FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.

Trial Locations (2)

20133

RECRUITING

Fondazione IRCCS Neurologico Carlo Besta, Milan

28938

NOT_YET_RECRUITING

CINAC-Hospital HM Puerta del Sur, Móstoles

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT04998864 - Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | Biotech Hunter | Biotech Hunter